- Email: [email protected]
5602305 Immunodeficient animal model for studying T cell-mediated immune
VII
PatentsALERT
includes providing the hepatocytes with a support, the support including extracellular matrix, the support having a configuration that permits each of at least a portion of the hepatocytes to form at least one apical surface and at least two discrete basal surfaces.
5602301 NON-HUMAN MAMMAL HAVING A GRAFT AND METHODS OF DELIVERING PROTEIN TO MYOCARDIAL TISSUE Field Loren J Indianapolis, IN, UNITED assigned to Indiana University Foundation
STATES
Described are preferred myocardial grafts of skeletal myoblasts or cardiomyocytes, and cellular compositions and methods useful in obtaining the grafts. The myocardial grafts are stable and can be used, for example, to deliver recombinant proteins directly to the heart.
5602305
5604229 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT Fujita Tetsuro; Sasaki Shigeo; Yoneta Masahiko; Mishina Tadashi; Adachi Kunitomo; Chiba Kenji Muko, JAPAN assigned to Yoshitomi Pharmaceutical Industries Ltd; Taito Co Ltd PCTNo. PCT/JP93/01515 Sec. 371 Date Jun. 17, 1994 Sec. 102(e) Date Jun. 17, 1994 PCT Filed Oct. 18, 1993 PCT Pub. No. WO94/08943 PCT Pub. Date Apr. 28, 1994. 2-Amino-1,3-propanediol compounds of the formula (I) (*See Patent for Chemical Structure*) (I) wherein R is an optionally substituted straight- or branched carbon chain, an optionally substituted aryl, an optionally substituted cycloalkyl or the like, and R2, R3, R4 and R5 are the same or different and each is a an alkyl, an aralkyl, an acyl or an hydrogen, alkoxycarbonyl, pharmaceutically acceptable salts thereof and immunosuppressants comprising these active ingredients. compounds as The 2-amino- 1,3_propanediol compounds of the present invention show immunosuppressive action and are useful for suppressing rejection in organ or bone marrow tranplantation, prevention and treatment of autoimmune diseases or as reagents for use in medicinal and pharmaceutical fields.
IMMUNODEFICIENT ANIMAL MODEL FOR STUDYING T CELL-MEDIATED IMMUNE Pober Jordan; Hughes Christopher C; Murray Allan G; Askenase Philip W; Petzelbauer Peter Guilford, CT, UNITED STATES assigned to Yale University The invention describes a novel present immunodeficient rodent model comprising an organ graft, such as a human skin graft, said graft containing microvessels lined by endothelial cells, human T lymphocytes and, optionally, at least one agent capable of substantially depleting the rodent’s Natural Killer cells. The human T lymphocytes are engrafted and circulating in the animal’s blood, enabling interaction with the endothelial cells which can be allogenic to the donor for the skin graft. The immunodeficient rodent used can be a SCID mouse. Preferably, the endothelial cells are provided by grafting said human skin with an This intact dermal superficial vascular plexus. immunodeficient rodent can be used as a model for studying inflammatory human immune responses of the engrafted T lymphocytes to foreign antigen as well as for studying human allograft rejection, e.g. human microvessel destruction and the T cell-endothelial cell in vivo interactions associated with a human allograft .
5605829 STROMA-DERIVED STEM CELL PROTEOGLYCAN GROWTH FACTOR
McGlave Philip B; Verfaillie Catherine Pankaj St Paul, MN, UNITED STATES Regents of the University of Minnesota
M; Gupta assigned to
An anionic macromolecular containing composition is disclosed that is capable of supporting conservation and differentiation of long-term bone marrow culture initiating cells in cultured mammalian hematopoietic cells. The composition disclosed is a mixture of glycoproteins, more specifically proteoglycans, which ^^^ -c - --..A1mv.l.w . ..o.mht r.rnotnr th-n 3cIn Ln
PatentsALERT
includes providing the hepatocytes with a support, the support including extracellular matrix, the support having a configuration that permits each of at least a portion of the hepatocytes to form at least one apical surface and at least two discrete basal surfaces.
5602301 NON-HUMAN MAMMAL HAVING A GRAFT AND METHODS OF DELIVERING PROTEIN TO MYOCARDIAL TISSUE Field Loren J Indianapolis, IN, UNITED assigned to Indiana University Foundation
STATES
Described are preferred myocardial grafts of skeletal myoblasts or cardiomyocytes, and cellular compositions and methods useful in obtaining the grafts. The myocardial grafts are stable and can be used, for example, to deliver recombinant proteins directly to the heart.
5602305
5604229 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT Fujita Tetsuro; Sasaki Shigeo; Yoneta Masahiko; Mishina Tadashi; Adachi Kunitomo; Chiba Kenji Muko, JAPAN assigned to Yoshitomi Pharmaceutical Industries Ltd; Taito Co Ltd PCTNo. PCT/JP93/01515 Sec. 371 Date Jun. 17, 1994 Sec. 102(e) Date Jun. 17, 1994 PCT Filed Oct. 18, 1993 PCT Pub. No. WO94/08943 PCT Pub. Date Apr. 28, 1994. 2-Amino-1,3-propanediol compounds of the formula (I) (*See Patent for Chemical Structure*) (I) wherein R is an optionally substituted straight- or branched carbon chain, an optionally substituted aryl, an optionally substituted cycloalkyl or the like, and R2, R3, R4 and R5 are the same or different and each is a an alkyl, an aralkyl, an acyl or an hydrogen, alkoxycarbonyl, pharmaceutically acceptable salts thereof and immunosuppressants comprising these active ingredients. compounds as The 2-amino- 1,3_propanediol compounds of the present invention show immunosuppressive action and are useful for suppressing rejection in organ or bone marrow tranplantation, prevention and treatment of autoimmune diseases or as reagents for use in medicinal and pharmaceutical fields.
IMMUNODEFICIENT ANIMAL MODEL FOR STUDYING T CELL-MEDIATED IMMUNE Pober Jordan; Hughes Christopher C; Murray Allan G; Askenase Philip W; Petzelbauer Peter Guilford, CT, UNITED STATES assigned to Yale University The invention describes a novel present immunodeficient rodent model comprising an organ graft, such as a human skin graft, said graft containing microvessels lined by endothelial cells, human T lymphocytes and, optionally, at least one agent capable of substantially depleting the rodent’s Natural Killer cells. The human T lymphocytes are engrafted and circulating in the animal’s blood, enabling interaction with the endothelial cells which can be allogenic to the donor for the skin graft. The immunodeficient rodent used can be a SCID mouse. Preferably, the endothelial cells are provided by grafting said human skin with an This intact dermal superficial vascular plexus. immunodeficient rodent can be used as a model for studying inflammatory human immune responses of the engrafted T lymphocytes to foreign antigen as well as for studying human allograft rejection, e.g. human microvessel destruction and the T cell-endothelial cell in vivo interactions associated with a human allograft .
5605829 STROMA-DERIVED STEM CELL PROTEOGLYCAN GROWTH FACTOR
McGlave Philip B; Verfaillie Catherine Pankaj St Paul, MN, UNITED STATES Regents of the University of Minnesota
M; Gupta assigned to
An anionic macromolecular containing composition is disclosed that is capable of supporting conservation and differentiation of long-term bone marrow culture initiating cells in cultured mammalian hematopoietic cells. The composition disclosed is a mixture of glycoproteins, more specifically proteoglycans, which ^^^ -c - --..A1mv.l.w . ..o.mht r.rnotnr th-n 3cIn Ln